NCCN 2021 Virtual Congress: Hematologic Malignancies™
The treatment of hematologic malignancies has become increasingly complex as a result of the rapid pace and number of advances in the biology and treatment of hematologic malignancies and the numerous drugs that have been approved or are in development, many with novel mechanisms of action. Clinicians who manage patients with hematologic malignances are challenged to stay abreast of advances in the evolving diagnostic and treatment landscape to ensure optimal patient outcomes.
The NCCN 2021 Virtual Congress: Hematologic Malignancies™ will focus on updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), new, emerging and novel therapeutic agents, advances in cancer care, and the practical management of patients with hematologic malignancies.
This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
The ultimate goal for NCCN continuing education is to change patient outcomes by improving the competence and performance of clinicians. The goal of the NCCN 2021 Virtual Congress: Hematologic Malignancies™ is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the management of patients with various hematologic malignancies.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.
A detailed list of learning objectives by session topic is available here.
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 13 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 13 contact hours.
NCCN designates this knowledge-based continuing education activity for 13 contact hours (1.3 CEUs) of continuing education credit. UAN: JA4008196-0000-21-092-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Maintenance of Certification (MOC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Maintenance of Certification program. Participants may earn up to 13 Lifelong Learning (Part II) credits. Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Medical Specialties Maintenance of Certification (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, the NCCN 2021 Annual Congress: Hematologic Malignancies has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:
MOC Part II CME Activity
- 13.00 AAPA Category 1 CME credit
- 13.00 AMA PRA Category 1 Credit™
- 13.00 ANCC contact hours
- 13.00 Participation
Click the Take Course button to start the credit claiming process.
CE/MOC credit should be claimed for the congress as a whole, not session by session. You may claim credit for the congress only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings until December 16, 2021.)
Pharmacists: you must complete all requirements for credit by November 30, 2021.